Conatus Posters at EASL Meeting Address MELD Score Dynamics and Outcomes in Decompensated Liver Cirrhosis Patients, Including...
April 21 2017 - 2:00AM
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced that two
posters co-authored by Conatus employees are being presented today
at The International Liver Congress™ 2017, the Annual Meeting of
the European Association for the Study of the Liver (EASL) in
Amsterdam, The Netherlands, April 19-23, 2017. The posters are the
result of a collaborative data analysis study with senior author W.
Ray Kim, M.D., Professor of Medicine, and lead author Ajitha
Mannalithara, Ph.D., Engineering Research Associate, both of the
Division of Gastroenterology and Hepatology at Stanford University
Medical Center.
Poster #FRI-485 entitled, “Model for end stage
liver disease [MELD] score dynamics in NASH [nonalcoholic
steatohepatitis] patients awaiting liver transplantation and
waitlist outcomes,” and poster #FRI-486 entitled “Model for end
stage liver disease score dynamics in patients awaiting liver
transplantation and waitlist outcomes,” will be displayed today,
Friday, April 21, from 8:00 a.m. to 6:00 p.m. CET. The full posters
are available in the Liver Disease Resources tab in the Data
section of the Conatus website at www.conatuspharma.com.
Summary of MELD Score Dynamics
EvaluationsAnalyses presented in both posters were based
on data extracted from the Organ Procurement and Transplantation
Network, for adults on the liver transplant waiting list on or
after January 1, 2010. For the -486 poster, patient outcomes were
assessed by the primary cause of cirrhosis (hepatitis C virus,
NASH, alcoholic liver disease, or unknown). For the -485 poster,
NASH cirrhosis patients were analyzed by baseline MELD score
(<15, 15-20, or >20). The different groups were then analyzed
for the ability of MELD score changes over a 12-week period to
predict transplant-free survival over two years.
Regardless of etiology and regardless of baseline
MELD score, patients whose MELD scores decreased by 2 points or
more had a lower incidence of death or liver transplantation.
Patients whose MELD scores increased had progressively higher
incidences of death or liver transplantation which correlated with
the degree of MELD score increase.
“One of the challenges to developing drugs in
decompensated cirrhosis patients in general, and specifically in
patients with NASH cirrhosis, is to identify an endpoint that
predicts long-term patient outcomes and is supported by clinical
data,” said David T. Hagerty, M.D., Executive Vice President of
Clinical Development of Conatus, “so we were eager to work with
Drs. Kim and Mannalithara in evaluating whether MELD score
progression or improvement could predict long-term patient
outcomes. Dr. Kim is an internationally recognized expert on the
MELD score and the knowledge provided by these efforts has helped
us to design the planned ENCORE-LF clinical trial in decompensated
NASH cirrhosis patients.”
About Conatus
PharmaceuticalsConatus is a biotechnology company focused
on the development and commercialization of novel medicines to
treat liver disease. Conatus is developing its lead compound,
emricasan, for the treatment of patients with chronic liver
disease. Emricasan is designed to reduce the activity of enzymes
that mediate inflammation and apoptosis. Conatus believes that by
reducing the activity of these enzymes, emricasan has the potential
to interrupt the disease progression across the spectrum of liver
disease. For additional information, please visit
www.conatuspharma.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. All statements other than statements of historical facts
contained in this press release are forward looking statements,
including statements regarding: the planned ENCORE-LF
clinical trial; and emricasan’s potential to reduce caspase
activity and interrupt disease progression across the spectrum of
liver disease. In some cases, you can identify forward-looking
statements by terms such as “may,” “will,” “should,” “expect,”
“plan,” “anticipate,” “could,” “intend,” “target,” “project,”
“contemplates,” “believes,” “estimates,” “predicts,” “potential” or
“continue” or the negative of these terms or other similar
expressions. These forward-looking statements speak only as of the
date of this press release and are subject to a number of risks,
uncertainties and assumptions, including: Conatus’ ability to
initiate and successfully complete current and future clinical
trials; the risk that the preclinical results may not be predictive
of future clinical results; the uncertainty of the U.S. Food and
Drug Administration’s and other regulatory agencies’ approval
processes and other regulatory requirements; and those risks
described in Conatus’ prior press releases and in the periodic
reports it files with the Securities and Exchange
Commission. The events and circumstances reflected in Conatus’
forward-looking statements may not be achieved or occur and actual
results could differ materially from those projected in the
forward-looking statements. Except as required by applicable law,
Conatus does not plan to publicly update or revise any
forward-looking statements contained herein, whether as a result of
any new information, future events, changed circumstances or
otherwise.
CONTACT: Alan Engbring
Conatus Pharmaceuticals Inc.
(858) 376-2637
aengbring@conatuspharma.com
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Sep 2023 to Sep 2024